SMO and acute myeloid leukemia: Glasdegib (PF-04449913) is a selective, small-molecule inhibitor of SMO that has demonstrated efficacy against AML cells both in vitro and in vivo in PDX mouse models.178 In this study, glasdegib was able to attenuate leukemia-initiation potential in serial transplant mouse models and sensitized AML cells to azacitidine.178 Glasdegib entered clinical trials, and a phase II study investigated the efficacy of glasdegib in combination with current standard AML therapies (NCT01546038).